← Research library

Determination of the prevalence of postcovid syndrome and assessment of the effectiveness of the drug Cortexin in the treatment of neurological disorders in patients with postcovid syndrome. Results of the multicenter clinical and epidemiological observational program CORTEX

Observational study · 2022

What was studied
CORTEX post-COVID program; 979 patients
Main finding
Observational follow-up recorded fatigue, cognitive and other post-COVID complaints and changes during treatment.

Proportion of neurological consultations with post-COVID complaints · 30% · A descriptive consultation figure, not a treatment response

Reported findings and study design

979 post-COVID patients; 674 neurologists contributed. Mean age 54.6 ± 0.45 years. Cortexin 10 or 20 mg IM for ten days; baseline, days 10–14 and day-30 visits.

Population or model CORTEX post-COVID program; 979 patients

Dose, route and schedule

Cortexin: 10 mg or 20 mg intramuscularly during a ten-day course. Administration frequency is not explicit in the indexed abstract.

Protocol source ↗ · Indexed publication abstract

Results · Previously retrieved indexed abstract; numerical statements checked against the saved source text
MeasureResultComparison, timing and statistics
Proportion of neurological consultations with post-COVID complaints30%A descriptive consultation figure, not a treatment response
Dose comparison20 mg described as more effective on anxiety-related symptomsNumerical score differences not supplied

The abstract contains garbled text about infection duration; it has not been interpreted into a study-duration estimate.

Source for these results ↗ · Reviewed 2026-10-29

Study limitations and source details

Study limitations

  • No randomized untreated control is described.
  • Symptom recovery and confounding remain plausible explanations; questionnaires are not wearable sleep stages.

Source details

Indexed abstract and citation checked via Europe PMC / PubMed; full methods and risk of bias not appraised.

Sources checked

Citation

Uncontrolled human reportEnglish abstract

Putilina MV, Mutovina ZY, Kurushina OV, Khalilova DM, Saverskaya EN, Stepanova SB, Khoreva MA, Starikov AS. Determination of the prevalence of postcovid syndrome and assessment of the effectiveness of the drug Cortexin in the treatment of neurological disorders in patients with postcovid syndrome. Results of the multicenter clinical and epidemiological observational program CORTEX Zh Nevrol Psikhiatr Im S S Korsakova 122(1):84-90. PMID 35175707

Study source ↗ · DOI 10.17116/jnevro202212201184 · Bibliography entry · Link to this summary

Related compounds

Editorial policy and evidence standards